日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

免疫效应细胞相关噬血细胞性淋巴组织细胞增生症样综合征的临床和细胞因子特征。

Srinagesh Hrishikesh K, Kramer Anne Marijn, Baird John H, Reschke Agnes, Sahaf Bita, Cancilla Juancarlos, Syal Shriya, Su Yi-Jiun, Agarwal Neha, Jensen Alexandria M, Schultz Liora M, Jeyakumar Nikeshan, Ramakrishna Sneha, Davis Kara L, Dahiya Saurabh, Feldman Steven A, Mackall Crystal L, Muffly Lori S, Miklos David B, Frank Matthew J

Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial

Axicabtagene Ciloleucel联合Atezolizumab治疗难治性弥漫性大B细胞淋巴瘤患者:1/2期ZUMA-6试验

Jacobson, Caron A; Westin, Jason R; Miklos, David B; Herrera, Alex F; Ritz, Jerome; Rodig, Scott; Arihara, Yohei; Cao, Subing; Sun, Jennifer; Mao, Daqin; Adhikary, Sabina; Neumann, Frank; Grechko, Nikolay; Locke, Frederick L

CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting

利索卡巴吉内马拉鲁塞输注后2周以上发生细胞因子释放综合征(CRS)或免疫复合物相关神经病变(ICANS)的情况很少见:来自临床试验和真实世界的数据

Hunter, Bradley D; Lunning, Matthew; Shadman, Mazyar; Ahmed, Sairah; Abramson, Jeremy S; Perales, Miguel-Angel; Ahmed, Nausheen; Mirza, Abu-Sayeef; Isufi, Iris; Frigault, Matthew J; Crombie, Jennifer L; Miklos, David B; Vasconcelos, Alberto; Crotta, Alessandro; Bernasconi, David; Roy, Debasmita; Bleickardt, Eric; Pasquini, Marcelo C; Kamdar, Manali

Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

异基因嵌合抗原受体T细胞产品Cemacabtagene Ansegedleucel/ALLO-501治疗复发/难治性大B细胞淋巴瘤:ALPHA2/ALPHA临床研究的I期经验

Locke, Frederick L; Munoz, Javier L; Tees, Michael T; Lekakis, Lazaros J; de Vos, Sven; Nath, Rajneesh; Stevens, Don A; Malik, Shahbaz A; Shouse, Geoffrey P; Hamadani, Mehdi; Oluwole, Olalekan O; Perales, Miguel-Angel; Miklos, David B; Fisher, Paul W; Feng, Amy; Navale, Lynn; Le Gall, John B; Neelapu, Sattva S

Donor regulatory T-cell therapy to prevent graft-versus-host disease

供体调节性T细胞疗法预防移植物抗宿主病

Meyer, Everett H; Pavlova, Anna; Villar-Prados, Alejandro; Bader, Cameron; Xie, Bryan; Muffly, Lori; Kim, Paige; Sutherland, Katherine; Bharadwaj, Sushma; Dahiya, Saurabh; Frank, Matthew; Arai, Sally; Johnston, Laura; Miklos, David; Rezvani, Andrew; Shiraz, Parveen; Sidana, Surbhi; Shizuru, Judy; Weng, Wen-Kai; Agrawal, Vaibhav; Putnam, Amy; Fernhoff, Nathaniel; Tamarisis, John; Lu, Ying; Pawar, Rahul D; McClellan, J Scott; Lowsky, Robert; Negrin, Robert S

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma

通过 CAR-T 细胞治疗多发性骨髓瘤后循环肿瘤 DNA 解析反应动力学和治疗耐药性

Hosoya, Hitomi; Carleton, Mia; Tanaka, Kailee; Sworder, Brian; Syal, Shriya; Sahaf, Bita; Maltos, Alisha M; Silva, Oscar; Stehr, Henning; Hovanky, Vanna; Duran, George; Zhang, Tian; Liedtke, Michaela; Arai, Sally; Iberri, David; Miklos, David; Khodadoust, Michael S; Sidana, Surbhi; Kurtz, David M

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel

静脉间输注时间对接受阿西卡巴基因西罗莱克治疗的复发/难治性大B细胞淋巴瘤患者的影响

Locke, Frederick L; Siddiqi, Tanya; Jacobson, Caron A; Nikiforow, Sarah; Ahmed, Sairah; Miklos, David B; Lin, Yi; Lunning, Matthew A; Hill, Brian T; Ghobadi, Armin; Hu, Zhen-Huan; Hemmer, Michael T; Zoratti, Michael J; Vunnum, Suresh; Tsang, Jonathan; Spooner, Clare; Smith, Harry; Fu, Christine; Patel, Anik; Miao, Harry; Shahani, Shilpa A; Mirjah, Debbie L; Xu, Hairong; Pasquini, Marcelo C

Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy

接受BCMA-CAR T细胞疗法的患者在自体干细胞移植后出现IEC-HS致命性复发

Ananth, Snegha; Torres, Nancy Eunice; Sahaf, Bita; Mikkilineni, Lekha; Fernandez-Pol, Sebastian; Salmi, Darren; Negrin, Robert; Shiraz, Parveen; Smith, Melody; Bharadwaj, Sushma; Weng, Wen-Kai; Kennedy, Vanessa E; Dahiya, Saurabh; Muffly, Lori; Miklos, David; Frank, Matthew J; Hosoya, Hitomi; Sidana, Surbhi

NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma

NKTR-255可增强复发/难治性大B细胞淋巴瘤患者接受CD19 CAR T细胞治疗后的完全缓解率

Ahmed, Sairah; DiPersio, John; Essell, James; Diefenbach, Catherine; Perales, Miguel-Angel; Castilla-Llorente, Cristina; Dahiya, Saurabh; Liu, Yi; Xu, Heng; Fanton, Christie; Chaudhry, Sohail; Lee, Zachary H; Marcondes, A Mario Q; Tagliaferri, Mary A; Zalevsky, Jonathan; Miklos, David; Turtle, Cameron J; McGuirk, Joseph

Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review

利用伊布替尼的免疫调节潜力改善T细胞介导的B细胞恶性肿瘤治疗效果:一篇叙述性综述

Miklos, David B; Riedell, Peter A; Bokun, Alex; Chavez, Julio C; Schuster, Stephen J